NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/15/2023
Back to search
Official data from USPTO
OMB KESIMPTA (OFATUMUMAB) 20 MG INJECTION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
08/15/2023
Trademark type
Combined
Nice classes
44
Filing date
02/18/2021
Registration date
08/15/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/15/2023
Last transaction
08/15/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2020-08-00
First use in commerce
2020-08-00
Drawing code
5
Owner type
99
Owner location
Basel, CH
Examiner
STEEL, ALYSSA
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized letters "OMB", displayed at a forty-five degree tilt, with the "O" in coral and the combined letters "MB" in teal, followed by the word "KESIMPTA" in a stylized brown font above the words "(ofatumumab) 20 mg injection" in a stylized brown font. The color white is not claimed and appears as background only.
Holders and representatives
Holders
Novartis AG
Representatives
Maury M. Tepper, III TEPPER & EYSTER, PLLC
Technical classification
Nice Classes
Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 44
Providing health information about pharmaceuticals containing monoclonal antibodies
Publications
History of USPTO decisions and trademark events.
42 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/15/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/13/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/12/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
07/12/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/12/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
07/12/2023
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
07/12/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/07/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/06/2023
EX4G
SOU EXTENSION 4 GRANTED
07/06/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/06/2023
IUAF
USE AMENDMENT FILED
06/28/2023
EXT4
SOU EXTENSION 4 FILED
06/28/2023
EEXT
SOU TEAS EXTENSION RECEIVED
06/28/2023
EISU
TEAS STATEMENT OF USE RECEIVED
06/28/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/14/2023
EX3G
SOU EXTENSION 3 GRANTED
06/12/2023
EXT3
SOU EXTENSION 3 FILED
06/12/2023
EEXT
SOU TEAS EXTENSION RECEIVED
06/12/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/14/2022
EX2G
SOU EXTENSION 2 GRANTED
12/12/2022
EXT2
SOU EXTENSION 2 FILED
12/12/2022
EEXT
SOU TEAS EXTENSION RECEIVED
12/12/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/14/2022
EX1G
SOU EXTENSION 1 GRANTED
06/12/2022
EXT1
SOU EXTENSION 1 FILED
06/12/2022
EEXT
SOU TEAS EXTENSION RECEIVED
06/12/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/14/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/19/2021
PUBO
PUBLISHED FOR OPPOSITION
10/19/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/29/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/16/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/15/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/15/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/15/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/14/2021
GNRT
NON-FINAL ACTION E-MAILED
09/14/2021
CNRT
NON-FINAL ACTION WRITTEN
09/14/2021
DOCK
ASSIGNED TO EXAMINER
09/14/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/20/2021
NWAP
NEW APPLICATION ENTERED
02/22/2021
Continuous trademark protection
Get notified about every new filing that threatens OMB KESIMPTA (OFATUMUMAB) 20 MG INJECTION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.